|
|
 | | | |
- close
- close
- close
- close
Regenicin, Inc. |
Suggest other news sources for this topic
WIKI ANALYSIS
Regenicin, Inc. (OTCBB: RGIN; Stock Twits: $RGIN) is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market.
Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
These living, self-to-self skin graft tissue are intended to form permanent skin tissue that will not be rejected by the immune system of the patient, a critical possibility in porcine or cadaver skin grafts used today.
The technology has been clinically tested in over 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.
PermaDerm™ is being designed to save lives, reduce healthcare costs by decreasing the patient’s stay in the Critical Care Unit and reduce the need for additional surgeries. An insurance company procedural code has been approved for reimbursement of costs to hospitals. The American Medical Association has assigned CPT (Current Procedural Terminology) code for cultured skin substitutes under the dermal substitute category which enables insurance companies to process and hospitals to be reimbursed for cultured skin substitutes once approved by the FDA.
Chairman and CEO, Randall McCoy recently pledged to return 22 million of his own personal shares back into Treasury (over 26% of the currently issued and outstanding shares of Regenicin) in a significant restructuring for the benefit of all sharholders. McCoy has more than 37 years of experience in the healthcare industry. His experience includes executive positions and scientific research and development. His previous employment includes George Washington University, Temple University Medical School and RCA/SRI International (Director of Life Sciences and Electronic Displays). Mr. McCoy has assisted both small and major pharmaceutical/device companies address FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and World market. Mr. McCoy currently has over 30 Patents US and International.
| |||||||
